Forty Seven Inc.
1661 Page Mill Road
Forty Seven Inc., a new biotechnology company specializing in cancer immunotherapy, is powering two upcoming anti-cancer studies with the Medidata Clinical Cloud®.
Forty Seven is named after the CD47 tumor cell protein that its lead molecule, Hu5F9-G4–an experimental monoclonal cancer drug–aims to attack. The biotech is embarking on a series of clinical trials to test its safety and efficacy in solid tumor and blood cancers. As part of these efforts, Forty Seven is using Rave in two of its upcoming Phase I and Phase II trials to streamline study operations, improve data quality and accessibility, and speed decision-making processes.
CEO: Jonathan MacQuitty, Ph.D., M.B.A.
Chief Business Officer: Craig Gibbs, PhD., M.B.A.
Chief Medical Officer: Chris Takimoto M.D. Ph.D.
Chief Patent Officer: Norm Kruse PhD., J.D